{"title":"Thrombotic and hemorrhagic complications in patients with severe and extremely severe COVID-19","authors":"M. V. Bychinin, T. Klypa, I. Mandel, P. Avdonin, D. I. Korshunov","doi":"10.17116/anaesthesiology202202124","DOIUrl":null,"url":null,"abstract":"Objective. To analyze the incidence and structure of thrombotic and hemorrhagic intensive care unit (ICU) with severe and extremely COVID-19. Material and methods. A retrospective single-center study included 442 consecutive intensive care unit patients with severe and extremely severe COVID-19. Results. Thrombotic complications occurred in 87 (19.7%) out of 442 patients. Thrombosis of deep and superficial veins of the lower extremities prevailed (n=42;9.5%). Arterial thrombotic complications were observed in 34 (7.7%) patients. Stroke (n=19;4.3%) and myocardial infarction (n=11;2.5%) prevailed among these ones. Respiratory therapy and norepinephrine infusion were more common in patients with thrombotic complications compared to those without thrombotic complications. These patients were characterized by prolonged ICU-and hospital-stay. Patients with thrombotic complications had higher concentrations of ferritin, C-reactive protein and troponin T at admission to ICU. According to thromboelastography data, patients with thrombotic complications had a hypercoagulable profile without significant between-group differences. Hemorrhagic complications developed in 23 patients (5.2%) including major bleeding in 15 cases. Gastrointestinal bleeding was the most common. Conclusion. Patients with severe and extremely severe COVID-19 have a high incidence of thrombotic and hemorrhagic complications. Prospective randomized trials are warranted to elucidate the risk-benefit ratio of different anticoagulation strategies in ICU patients with new coronavirus infection. © 2022, Media Sphera Publishing Group. All rights reserved.","PeriodicalId":297480,"journal":{"name":"Anesteziologiya i reanimatologiya","volume":"38 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anesteziologiya i reanimatologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/anaesthesiology202202124","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
重症和极重症COVID-19患者的血栓和出血性并发症
目标。目的:分析重症和极重度COVID-19血栓和出血性重症监护病房(ICU)的发生率和结构。材料和方法。一项回顾性单中心研究纳入了442例重症和极重症COVID-19患者。结果。442例患者中有87例(19.7%)发生血栓性并发症。下肢深静脉和浅静脉血栓发生率最高(n=42;9.5%)。动脉血栓形成并发症34例(7.7%)。其中以卒中(n=19, 4.3%)和心肌梗死(n=11, 2.5%)为主。呼吸治疗和去甲肾上腺素输注在有血栓性并发症的患者中比没有血栓性并发症的患者更常见。这些患者的特点是icu和住院时间延长。有血栓性并发症的患者入院时铁蛋白、c反应蛋白和肌钙蛋白T浓度较高。根据血栓弹性成像数据,有血栓性并发症的患者具有高凝状态,组间无显著差异。出现出血性并发症23例(5.2%),其中大出血15例。消化道出血最为常见。结论。重症和极重症COVID-19患者血栓和出血性并发症的发生率很高。需要前瞻性随机试验来阐明新型冠状病毒感染ICU患者不同抗凝策略的风险-效益比。©2022,Media Sphera出版集团。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。